- Email Enquiry - clientservices@emcenvision.com
Our team comprises seasoned professionals with deep expertise across healthcare, pharmaceuticals, market access, health economics, and medical affairs. With decades of experience spanning global and emerging markets, we bring a strategic, evidence-driven approach to accelerating access to innovative therapies and transforming healthcare landscapes.
Our team consists of experienced professionals from around the world, bringing diverse expertise to deliver exceptional value in healthcare solutions.
Partner with us to simplify complexity, demonstrate value, and accelerate access to innovative healthcare solutions. Let’s shape a healthier future together.
+971 56 148 5416 / +971 56 216 9558
Unit 13-14, 1st Floor Princess Building, Sheikh Zayed Road, PO Box 453505, Dubai, UAE
Fayaz is an accomplished Healthcare Executive with a 25-year career across academia, government, and the pharmaceutical industry. His leadership roles have spanned Market Access & Pricing, Value Evidence, and Medical Affairs, and his work has had a significant impact in various regions, including Europe, Emerging Markets and the Middle East Africa.
Fayaz’s leadership has driven critical initiatives in Clinical Development, Health Economics & Real-World Evidence Generation, Technology Value Assessment & Communication, Strategic Resource Management and Customer Engagement. His deep understanding of healthcare system dynamics, has informed public health policy. In the pharmaceutical industry, he has fostered collaboration to identify unmet needs and accelerate access to innovative therapies. Fayaz is a transformational leader who bridges the gap between science, policy, and patient care.
Ramy is an accomplished senior leader with over two decades of experience in the pharmaceutical industry, with a track record of leading commercial excellence initiatives across various therapeutic areas.
He has extensive regional experience, managing portfolios valued up to $1 billion across Europe, the Middle East, Africa, and Russia & CauCar. Ramy has led Commercial business units within Primary Care and Specialty Care, focusing on Antimicrobial therapies, Covid, and Rare Diseases. He has developed strategies for both novel and life cycle assets, ensuring launch excellence for new therapies in multiple markets. During the Covid pandemic, he worked with Country Leads and Government stakeholders to manage treatment delivery.
Ramy has also driven initiatives to enhance therapy access in LMIC markets. As a certified Life Coach, he is passionate about connecting with other leaders to enhance their impact.
Toby has 28 years of experience as a health economist in the academic, pharmaceutical and consultancy sectors. During this time, Toby spent 13 years in UK pharma company affiliates gaining access and reimbursement for over 30 new medicines, as well as in global and EU regional teams. He has spent seven years within the consultancy sector working both as an independent contractor at IQVIA, as well as directly employed at Director level within FIECON and PRMA Consulting.
During his time in the pharmaceutical and consultancy sectors, Toby has gained global and EU experience developing global value dossiers, economic models, real world studies and evidence generation strategies. Toby also led and mentored teams of health economists and market access experts.
Kashmira is a seasoned consultant with more than five years of experience in pharmaceutical Pricing and Market Access. Her skill set encompasses the formulation of robust pricing, reimbursement, and access strategies, as well as executing qualitative and quantitative research tasks, stakeholder mapping, and crafting value messaging and communication strategies across the Middle East and Africa.
Kashmira holds a wealth of proficiency in architecting successful market launch strategies tailored for the GCC region, particularly within innovative therapies for rare diseases.
Her impact extends to conducting advisory boards, seamlessly managing logistics, and driving stakeholder engagement for a multitude of pivotal projects. She brings a wealth of experience in evaluating usability and functionality of prototypes or new healthcare related software, integrating digital solutions and developing decision support tools and algorithms.
Ali is a health economics and outcomes research (HEOR) expert with a strong background in market access, patient-reported outcomes, and medical research. He has a proven track record of success in developing strategic brand plans that have led to the successful launch and access of new medications in Saudi Arabia.
Ali’s expertise in HEOR and HTA, combined with his deep understanding of the Saudi healthcare system, has enabled him to effectively translate complex economic data into actionable insights for local payers and decision-makers. This has resulted in improved patient access to essential medications in therapeutic areas such as diabetes, immunology, and oncology.
Eleonora is a Health Economist with over 17 years of experience in the harmaceutical industry, holding roles in Clinical Research, Health Economics, Outcomes Research, and Market Access at companies such as Wyeth-Whitehall, Pfizer, and Bristol-Myers Squibb.
Her experience spans both local and regional responsibilities, including markets in Chile, Colombia, Peru, and Venezuela. She is a member of ISPOR and served as President of the Argentine Chapter of ISPOR from 2009 to 2011. She has led and contributed to numerous economic evaluation studies and is the author or co-author of several articles on these topics, published in national and international journals.
Laura, a senior medical affairs leader has over 30 years of experience in the pharmaceutical industry across multiple therapeutic areas and geographies. Trained as Internal Medicine and Clinical Pharmacologist with clinical research and medical affairs experience at global and Emerging Markets with great focus within LATAM and the Middle East.
At GSK, Laura led the regional team across multiple TAs, with cross functional interaction and set up the Oncology structure across all Emerging Markets attracting the right talent and capabilities from science to the bench ,from clinical research regulatory to successful launches under different business models. Previously worked at BMS and Roche with multiple responsibilities at global and regional level for Immunology ,HIV, Hepatitis, CNS & Rare diseases.
Elif is a distinguished healthcare leader with over 25 years of experience spanning the pharmaceutical industry, clinical practice, and strategic medical affairs. She has held prominent roles at global, regional, and local levels, driving execution of medical strategies and clinical trials across diverse therapeutic areas, including oncology, cardiovascular health, metabolic disorders, respiratory diseases, rare diseases, and vaccines.
Elif is recognized for her transformative leadership, having successfully launched life-saving therapies in emerging and developed markets, including immuno-oncology and targeted treatments. She has an extensive track record in global strategy
Dr. Amro El Saddik is a senior medical affairs leader with close to 30 years of experience working across the pharmaceutical industry, academia and Hospital setting. He is a physician with specialised expertise in Oncology and Cell and Gene Therapy.
He was previously the Oncology Excellence Lead, and the Cell Therapy program Director at Burjeel Holdings, UAE. His role was to lead the team to establish Burjeel Medical City as a Centre Of Excellence in Oncology and Haematology.
Amro also previously held a number of pharmaceutical industry roles including the Gulf Oncology Senior Medical Manager at Pfizer, and as the Global Medical Manager for Cell and Gene Therapy at GSK, MENA organisation. He is also an Assistant Professor of Clinical pathology in Mansoura University, Egypt.
With over 17 years of experience in project management and operations leadership, Yarineth brings a holistic approach to helping organizations succeed, combining operational expertise with coaching and facilitation. She has successfully led global initiatives, ensuring compliance, governance, and operational efficiency across multiple regions.
A key highlight of her career was managing medical operations across 20+ countries during the COVID-19 pandemic, demonstrating strong leadership and adaptability in one of the industry’s most challenging periods. Yarineth is a certified as a Project Management Professional (PMP), SDI Facilitator, and Lego Serious Play Facilitator, with additional certifications in meditation, breathing, and sacred geometry. These allow her to offer a unique coaching approach that integrates personal well-being with professional success.
Imran Kausar, is a seasoned pharmaceutical executive with specific expertise in gene therapy, rare diseases and ATMPs. With nearly two decades of experience in large pharmaceuticals (Pfizer, Novartis) as well as biotechs (InterMune, Ionis/Akcea, AveXis).
He has worked in medical affairs and general management leading large teams across Europe responsible for P&L of over >$600m. He has launched numerous drugs over his career, for adults and children, mainly in rare diseases. Most recently he was responsible for delivering the gene therapy portfolio across Europe at Novartis Gene Therapies where he built teams to launch and commercialise Zolgensma (the highest grossing gene therapy to date) and Luxturna. Imran is based in London where he also is a Non-executive Director for a national cancer charity.
Claudia is a physician who holds an MSc and PhD in Epidemiology & Biostatistics, focusing on epidemiology methods and comparative effectiveness studies using real-world data, and a second master’s in Business Intelligence with a focus on data sciences and AI methods in healthcare. She has over 18 years of experience in Pharma R&D, Health Outcomes, and Medical Affairs at LOC, regional, and global levels. She previously worked as an epidemiologist and health outcomes consultant across academic, private, public, and government institutions.
Claudia has led projects in epidemiology, health outcomes, medical decision-making, data collaborations, and RWD in emerging markets, focusing on decision analysis, evidence generation strategies, and optimizing asset value by studying disease patterns and treatment impacts in multiple therapeutic areas.